Tdspharm Co (464280) Fair Value & Analysis
Healthcare · KR · Market cap 29.1B KRW
Fair value as of: Jul 22, 2026
From 12 valuation models · updated 18 days ago
Share price −3.8% over the past month.
Below-average quality, screening 124% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (41/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (8,764 KRW). The market is more pessimistic than our downside scenario.
- A fairly wide model range (8,764 KRW to 16,277 KRW) leaves room in how you read the outcome.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
24‑month range 4,525 KRW – 52,000 KRW · fair‑value band 8,764 KRW – 16,277 KRW · the 5,590 KRW price screens below the 12,521 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Tdspharm Co (464280) currently trades at 5,590 KRW, while our model-based Fair Value estimate is 12,521 KRW, implying the stock looks roughly 124.0% undervalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Tdspharm Co generated revenue of 30.4B KRW at a net margin of 16.6%. Revenue grew 52.9% year over year. It earns a return on equity of 12.2%. Net debt stands at 6.4B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 8,764 KRW (bear case) to 16,277 KRW (bull case); at 5,590 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 53% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at 124%, 464280 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 12 models by family
Widest divergence: Multiples (13,045 KRW) versus Asset-Based (5,420 KRW). Highest evidence: ROIC Compounder (72).
Notify me when 464280 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 8
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Tdspharm Co., Ltd. researches, develops, and produces pharmaceuticals and cosmetics in South Korea and internationally. It offers general medicines, prescription drugs, and non-medicinal products. The company was founded in 2002 and is based in Seongnam-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Tdspharm Co reported revenue of 27.6B KRW in FY2025 versus 19.8B KRW in FY2021, a compound +8.7%/yr. Reported net income was 4.3B KRW in FY2025, compounding +20.0%/yr from FY2021.
Watch 464280: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - General · 76 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,182 | $396.77 | -66% |
| Johnson & Johnson, JNJ | $257.59 | $169.04 | -34% |
| AbbVie Inc ABBV | $254.49 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €226.68 | -42% |
| Merck & Co MRK | €108.08 | €121.54 | +12% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| AstraZeneca PLC AZN | $171.61 | $129.54 | -25% |
| Novo Nordisk A/S NOVOB | kr 329.90 | kr 409.46 | +24% |
| Amgen Inc AMGN | $363.39 | $252.02 | -31% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
Compare Tdspharm Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Tdspharm Co (464280) overvalued or undervalued?
What is the fair value of 464280?
What is the quality score of 464280?
What is the revenue of Tdspharm Co (464280)?
What is the net profit margin of 464280?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Tdspharm Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.